External quality assessment demonstrates that PD‐L1 22C3 and SP263 assays are systematically different-Reference-Cited by-同舟云学术

External quality assessment demonstrates that PD‐L1 22C3 and SP263 assays are systematically different

Published:2019-12-17 Issue:2 Volume:6 Page:138-145
ISSN:2056-4538
Container-title:The Journal of Pathology: Clinical Research
language:en
Short-container-title:J Pathol Clin Res

Author:

Dodson Andrew¹^ORCID,Parry Suzanne¹,Lissenberg‐Witte Birgit²,Haragan Alex³,Allen David⁴,O'Grady Anthony⁵,McClean Emma⁶,Hughes Jamie¹,Miller Keith¹,Thunnissen Erik⁷

Affiliation:

1. UK National External Quality Assessment Scheme for Immunocytochemistry and In‐Situ Hybridisation London UK

2. Department of Epidemiology and BiostatisticsAmsterdam UMC, Vrije Universiteit Amsterdam Amsterdam The Netherlands

3. Department of PathologyRoyal Liverpool and Broadgreen University Hospitals Liverpool UK

4. HSL‐Advanced Diagnostics London UK

5. Department of PathologyRoyal College of Surgeons in Ireland, Beaumont Hospital Dublin Ireland

6. Oncology, Haematology and Cellular PathologyGuy's and St Thomas' NHS Foundation Trust London UK

7. Department of PathologyAmsterdam UMC, Vrije Universiteit Amsterdam Amsterdam The Netherlands

Publisher

Wiley

Subject

Pathology and Forensic Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cjp2.153

Reference35 articles.

1. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology

2. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

3. Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

4. Current Status of Companion and Complementary Diagnostics: Strategic Considerations for Development and Launch

5. Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapeutic strategies in hepatopancreatobiliary cancers;Principles of Immunotherapy Breast and Gastrointestinal Cancers;2025

2. Immunohistochemistry for prediction of response to immunotherapy;Diagnostic Histopathology;2024-09

3. Best-Practice Biomarker Testing of Oesophago-Gastric Cancer in the UK: Expert Consensus Recommendations Developed Using a Modified Delphi;Clinical Oncology;2024-08

4. PD‐L1 expression in patients with non‐small‐cell lung cancer is associated with sex and genetic alterations: A retrospective study within the Caucasian population;Thoracic Cancer;2024-06-11

5. PD-L1 expression in squamous cervical carcinomas of Mozambican women living with or without HIV;Scientific Reports;2024-06-05